Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07205900 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus
A Phase 2 study of Obesity and Obese, sponsored by Hanmi Pharmaceutical Company Limited.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
- 13
- Study locations
NCT07205900: Recruiting Phase 2 study of Obesity and Obese, sponsored by Hanmi Pharmaceutical Company Limited.
NCT07205900 is a Phase 2 study of Obesity and Obese that is actively recruiting participants, run by Hanmi Pharmaceutical Company Limited. The registered enrollment target is 250 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (69% lower). The trial reports 13 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07205900, a Phase 2 study of Obesity and Obese, is actively recruiting participants, sponsored by Hanmi Pharmaceutical Company Limited.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
- 13
- Study locations
Study Summary
This Study is a Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Obese or Overweight Subjects Without Diabetes Mellitus.
Primary Outcome
Percent change in body weight from Week 1 to Week 37, measured using a standardized, calibrated scale under fasting conditions.
Interventions
- DRUG HM15275
- DRUG Placebo of HM15275
Study Locations (13)
North Carolina
- Accellacare of Cary - Cary Medical Group - Cary
- Accellacare of Hickory - Hickory
- Raleigh Medical Group, P.A. - Raleigh
- Accellacare of Piedmont - Piedmont HealthCare - Statesville
- Accellacare of Wilmington, LLC - Wilmington
- Accellacare of Winston Salem - Winston-Salem
Tennessee
- Accellacare of Bristol-PAC of Tennessee - Bristol
- Bristol-Internal Medicine and Pediatric Associates of Bristol, P.C. - Bristol
California
- ProSciento Inc - Chula Vista
Illinois
- Accellacare of Duly - Duly Oak Lawn - Oak Lawn
Iowa
- Accellacare of McFarland - Ames
South Carolina
- Accellacare of Charleston - Mt. Pleasant
Texas
- Velocity Clinical Research, Dallas - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2025-12-02 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
What NCT07205900 shows while recruiting
NCT07205900 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (69% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which HM15275 is the first listed.
NCT07205900 lists 13 locations in 7 states (North Carolina, Tennessee, California).
Frequently Asked Questions
What is clinical trial NCT07205900 about?
NCT07205900 is a clinical study titled "Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus". This Study is a Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Obese or Overweight Subjects Without Diabetes Mellitus.
What is the current status of trial NCT07205900?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2025-12-02. Estimated completion is 2027-01.
What conditions does trial NCT07205900 study?
This clinical trial studies the following conditions: Obesity, Obese.
What interventions are being tested in trial NCT07205900?
The interventions under investigation include: HM15275 (DRUG), Placebo of HM15275 (DRUG).
Who is sponsoring clinical trial NCT07205900?
This trial is sponsored by Hanmi Pharmaceutical Company Limited, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07205900 being conducted?
This trial has 13 study locations across California, Illinois, Iowa, North Carolina, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07205900's enrollment target sits among peer trials
250 255th of 1053 higher than 789 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI